SCHEMBL4864188

SCHEMBL4864188

Cc1ccnc(NNC(=O)C(C2CCC(C)(C)CC2)N(O)C=O)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.36
POLB P06746 3/20 0.35
KDM4E B2RXH2 1/20 0.34
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
FASN P49327 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
EPHX2 P34913 1/20 0.32
LMNA P02545 1/20 0.32
JAK2 O60674 1/20 0.31
NTRK1 P04629 1/20 0.31
FYN P06241 1/20 0.31
FGR P09769 1/20 0.31
SRC P12931 1/20 0.31
FER P16591 1/20 0.31
SLC6A2 P23975 1/20 0.31
ZAP70 P43403 1/20 0.31
NTRK3 Q16288 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867317 0.89 HTT (0.40) SYKPOLBKDM4EKMT2ASMN1; SMN2
SCHEMBL4866392 0.88 POLB (0.36) SYKPOLBKDM4EKMT2ASMN1; SMN2
SCHEMBL4864288 0.87 GAA (0.40) SYKGAA
SCHEMBL4870371 0.85 POLB (0.36) SYKPOLBKDM4ESMN1; SMN2FASN
SCHEMBL4870898 0.84 POLB (0.36) SYKPOLBKDM4EKMT2ASMN1; SMN2
SCHEMBL4872971 0.82 ALDH1A1 (0.39) SYKKDM4EKMT2ASMN1; SMN2NPC1
SCHEMBL4873664 0.79 KDM4E (0.36) SYKPOLBKDM4EKMT2ASMN1; SMN2
SCHEMBL4869265 0.78 SRC (0.32) SRC
SCHEMBL4864359 0.77 CRHBP (0.38) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
SCHEMBL4868014 0.75 GAA (0.43) SYKALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332485-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORP (US) 2008-02-19 US claimed
US-20060160802-A1 Peptide deformylase inhibitors GLAXO GROUP LIMITED 2006-07-20 US claimed
WO-2005005456-A2 PEPTIDE DEFORMYLASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-01-20 WO claimed
US-7332485-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORP (US) 2008-02-19 US disclosed
US-20060160802-A1 Peptide deformylase inhibitors GLAXO GROUP LIMITED 2006-07-20 US disclosed
WO-2005005456-A2 PEPTIDE DEFORMYLASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160802-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 SYK 4390/4885POLB 2001/4885KDM4E 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.